LMX 4

This brand name is authorized in Cyprus, New Zealand, Turkey, UK.

Active ingredients

The drug LMX 4 contains one active pharmaceutical ingredient (API):

1	Lidocaine UNII 98PI200987 - LIDOCAINE
	Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane.
	Read more about Lidocaine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LMX4 Cream	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D04AB01	Lidocaine	D Dermatologicals → D04 Antipruritics, incl. antihistamines, anesthetics, etc. → D04A Antipruritics, incl. antihistamines, anesthetics, etc. → D04AB Anesthetics for topical use
Discover more medicines within D04AB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	141892, 321995
NZ	Medicines and Medical Devices Safety Authority	15921
TR	İlaç ve Tıbbi Cihaz Kurumu	8680869370012, 8680869370357, 8680869370401